From cosubstrate similarity to inhibitor diversity--inhibitors of ADP-ribosyltransferases from kinase inhibitor screening.
暂无分享,去创建一个
W. Sippl | K. Aktories | M. Jung | T. Jank | S. Shekfeh | Joachim H. C. Orth | P. Papatheodorou | Carsten Schwan | B. Maurer | Ulf Mathias
[1] H. Mannherz,et al. Photorhabdus luminescens Toxins ADP-Ribosylate Actin and RhoA to Force Actin Clustering , 2010, Science.
[2] Kaixian Chen,et al. A fluorometric assay of SIRT1 deacetylation activity through quantification of nicotinamide adenine dinucleotide. , 2009, Analytical biochemistry.
[3] H. Kantarjian,et al. Imatinib and beyond—exploring the full potential of targeted therapy for CML , 2009, Nature Reviews Clinical Oncology.
[4] Simon Messner,et al. Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites , 2009, Nucleic acids research.
[5] A. Kazantsev,et al. Biological and Potential Therapeutic Roles of Sirtuin Deacetylases , 2008, Cellular and Molecular Life Sciences.
[6] G. Schulz,et al. Structure and mode of action of a mosquitocidal holotoxin. , 2008, Journal of molecular biology.
[7] A. Ashworth,et al. Targeted therapy for cancer using PARP inhibitors. , 2008, Current opinion in pharmacology.
[8] A. Pautsch,et al. C3 exoenzymes, novel insights into structure and action of Rho-ADP-ribosylating toxins , 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.
[9] C. Kunick,et al. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. , 2006, Journal of medicinal chemistry.
[10] G. Schulz,et al. Structure of the mosquitocidal toxin from Bacillus sphaericus. , 2006, Journal of molecular biology.
[11] Brian J Eastwood,et al. A Comparison of Assay Performance Measures in Screening Assays: Signal Window, Z' Factor, and Assay Variability Ratio , 2006, Journal of biomolecular screening.
[12] Stuart Johnson,et al. An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.
[13] D. Corda,et al. Physiological relevance of the endogenous mono(ADP‐ribosyl)ation of cellular proteins , 2005, The FEBS journal.
[14] M. Jung,et al. In vitro assays for the determination of histone deacetylase activity. , 2005, Methods.
[15] K. Aktories,et al. Two-site autoinhibition of the ADP-ribosylating mosquitocidal toxin (MTX) from Bacillus sphaericus by its 70-kDa ricin-like binding domain. , 2004, Biochemistry.
[16] K. Aktories,et al. Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins , 2004, Microbiology and Molecular Biology Reviews.
[17] P. Hergenrother,et al. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors. , 2004, Analytical biochemistry.
[18] K. Aktories,et al. Rho-modifying C3-like ADP-ribosyltransferases. , 2004, Reviews of physiology, biochemistry and pharmacology.
[19] T. Sugimura,et al. Mono(ADP-ribosyl)ation of DNA by apoptosis-inducing protein, pierisin. , 2002, Nucleic acids research. Supplement.
[20] M. Rodnina,et al. Inactivation of the Elongation Factor Tu by Mosquitocidal Toxin-Catalyzed Mono-ADP-Ribosylation , 2002, Applied and Environmental Microbiology.
[21] K. Aktories,et al. The ADP-ribosylating Mosquitocidal Toxin from Bacillus sphaericus , 2002, The Journal of Biological Chemistry.
[22] K. Aktories,et al. Characterization of the Enzymatic Component of the ADP-Ribosyltransferase Toxin CDTa from Clostridium difficile , 2001, Infection and Immunity.
[23] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[24] V. D. Dyachenko,et al. Synthesis of arylmethylenecyanothioacetamides in a Michael reaction , 1998 .
[25] G. Corthier,et al. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196 , 1997, Infection and immunity.
[26] M. Wilm,et al. Clostridium novyi α-Toxin-catalyzed Incorporation of GlcNAc into Rho Subfamily Proteins* , 1996, The Journal of Biological Chemistry.
[27] A. Hall,et al. Microinjection of recombinant p21rho induces rapid changes in cell morphology , 1990, The Journal of cell biology.
[28] M. Hagiwara,et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. , 1990, The Journal of biological chemistry.
[29] S. Narumiya,et al. Asparagine residue in the rho gene product is the modification site for botulinum ADP-ribosyltransferase. , 1989, The Journal of biological chemistry.
[30] E. Rubin,et al. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain , 1988, Infection and immunity.
[31] K. Aktories,et al. Clostridium botulinum type C produces a novel ADP‐ribosyltransferase distinct from botulinum C2 toxin , 1987, FEBS letters.
[32] D. T. Elmore,et al. The behaviour of urokinase and porcine kidney cell plasminogen activator towards some synthetic peptides. , 1984, Thrombosis research.
[33] Gill Dm,et al. ADP-ribosylation of membrane proteins and activation of adenylate cyclase by cholera toxin in fat cell ghosts from euthyroid and hypothyroid rats , 1979 .
[34] E. Kun,et al. Covalent modification of proteins by metabolites of NAD+. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[35] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.